Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Soliris Market Expansion From $ Billion In 2026 To $ Billion In 2030
The market for Soliris has experienced notable expansion over recent years. Projections indicate an increase from $2030.44 million in 2025 to $2191.9 million by 2026, reflecting a compound annual growth rate of 8.0%. Factors driving the historical growth include the lack of adequate treatments for uncommon diseases, effective clinical outcomes in managing paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, incentives provided through orphan drug regulations, enhancements in patient survival rates, and the scarcity of competing therapeutic options.
Market analysts project strong growth for the soliris market in the coming years. By 2030, it is anticipated to reach $2941.58 million, driven by a compound annual growth rate (CAGR) of 7.6%. This forecasted expansion can be linked to several factors, including extending its application to additional complement-mediated diseases, heightened awareness of rare conditions, advancements in genetic diagnostics, greater healthcare funding allocated to orphan drugs, and the implementation of long-term therapy adherence initiatives. Key trends shaping this period encompass a growing preference for complement inhibitor therapies, an intensified focus on ultra-rare diseases, the broader utilization of long-term biologic treatments, an increase in genetic testing for rare disorders, and the robust growth of the high-value orphan drug market.
Download A Free Sample Report For Comprehensive Market Insights:
Soliris Market Growth Drivers: What Factors Are Accelerating Expansion?
Growing frequency of uncommon blood disorders is anticipated to stimulate future expansion of the soliris market. These rare blood disorders involve infrequent conditions that impact blood production, components, or clotting mechanisms, including diseases like hemophilia, sickle cell anemia, and thalassemia. Higher occurrence rates of these disorders stem from enhanced diagnostic methods, increased public awareness, alongside genetic and environmental influences. By blocking the complement protein C5, Soliris aids patients with rare blood disorders in avoiding excessive complement activation, thereby lowering risks of serious complications such as hemolysis and organ damage, which ultimately improves overall disease control and patient health outcomes. For example, in May 2024, the National Health Service (NHS) England, a UK-based government-funded healthcare organization, reported that around 17,000 individuals live with sickle cell disease—an inherited blood condition—in England, with roughly 250 new diagnoses occurring each year. Thus, the rising incidence of rare blood disorders is fueling growth within the soliris market.
Soliris Market Driver: Growing Investment In Rare Disease Research Drive Soliris Market Expansion
Continued expansion of the Soliris market is expected to be driven forward by enhanced financial commitments to rare disease research. This surge in investment is propelled by greater recognition of unmet medical needs, progress in genomic technologies, and prospects for transformative therapies that significantly enhance patient outcomes. Funding directed at rare disease research benefits Soliris by deepening insights into underserved medical conditions, thereby boosting demand for powerful treatment options. As an illustration, in July 2023, the Department of Health and Social Care, a UK-based government agency, allocated major resources, including USD 834.20 million (£790 million) for Biomedical Research Centers, USD 15.06 million (£12 million) to the UK Rare Disease Research Platform, and USD 50.20 million (£40 million) for the NIHR BioResource—which links genetic data with clinical characteristics across 50 rare diseases to accelerate diagnostic and therapeutic progress. Consequently, growing investment in rare disease research is propelling the expansion of the Soliris market.
Soliris Market Segments: Where Are The Largest Growth Opportunities?
The soliris market covered in this report is segmented –
1) By Type: Plasma Exchange, Plasma Infusion
2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Soliris Market Trends: What Is Shaping Future Industry Growth?
A central focus within the soliris market is the advancement of biologic therapies specifically designed for neuromyelitis optica spectrum disorder (NMOSD), aimed at improving treatment outcomes for this rare condition. This development represents a notable milestone in addressing NMOSD, a severe and uncommon autoimmune disorder that impacts the central nervous system, by offering an effective solution that curbs disease relapses and limits ongoing neurological deterioration. To illustrate, during October 2023, approval was granted to AstraZeneca PLC, a pharmaceutical enterprise based in the United Kingdom, for its product Soliris (eculizumab) by China’s National Medical Products Administration (NMPA). This authorization applies to adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies (Ab+), making it the inaugural complement inhibitor to receive such approval for NMOSD management in the Chinese market.
Soliris Market Major Participants And Competitive Dynamics
Major companies operating in the soliris market are Pfizer
Access The Complete Soliris Market Report:
Soliris Market Regional Analysis And Leading Geography
North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model